Cefditoren pivoxil - A review of its use in the treatment of bacterial infections
Cefditoren pivoxil - A review of its use in the treatment of bacterial infections
复制标题
DOI：
10.2165/00003495-200464220-00009
复制
发表时间：
2004-01-01
期刊：
影响因子：
11.5
通讯作者：
Curran, MP
中科院分区：
文献类型：
--
作者：
Wellington, K;Curran, MP
头孢妥仑Pivoxil(spectracef(R)，Meiact(R))是第三代口服头孢菌素，对包括革兰氏阳性和阴性细菌在内的病原体具有广泛的活性，对许多常见的β-内酰胺酶都是稳定的。头孢妥仑Pivoxil被批准用于治疗急性加重期慢性支气管炎(AECB)、轻到中度社区获得性肺炎(CAP)、急性上颌鼻窦炎、急性咽炎/扁桃体炎和简单皮肤和皮肤结构感染(适应症可能因国家而异)。在成人和青少年的临床试验中，头孢妥仑Pivoxil对AECB、CAP、急性上颌鼻窦炎、急性咽炎/扁桃体炎和简单皮肤和皮肤结构感染显示出良好的临床和细菌学疗效，并且总体耐受性良好。因此，对于患有特殊呼吸道或皮肤感染的成人和青少年患者，头孢妥仑匹酯是一个很好的选择，特别是如果担心肺炎链球菌对青霉素的敏感性降低，或在常见的社区获得性病原体中存在β-内酰胺酶介导的耐药性。
Cefditoren pivoxil (Spectracef(R), Meiact(R)) is a third-generation oral cephalosporin with a broad spectrum of activity against pathogens, including both Gram-positive and -negative bacteria, and is stable to hydrolysis by many common beta-lactamases. Cefditoren pivoxil is approved for use in the treatment of acute exacerbations of chronic bronchitis (AECB), mild-to-moderate community-acquired pneumonia (CAP), acute maxillary sinusitis, acute pharyngitis/tonsillitis and uncomplicated skin and skin structure infections (indications may differ between countries).In clinical trials in adults and adolescents, cefditoren pivoxil demonstrated good clinical and bacteriological efficacy in AECB, CAP, acute maxillary sinusitis, acute pharyngitis/tonsillitis and uncomplicated skin and skin structure infections and was generally well tolerated. Thus, cefditoren pivoxil is a good option for the treatment of adult and adolescent patients with specific respiratory tract or skin infections, particularly if there is concern about Streptococcus pneumoniae with decreased susceptibility to penicillin, or P-lactamase-mediated resistance among the common community-acquired pathogens.